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Abstract
Background: More than three billion populations are living under the threat of Japanese encephalitis in South East
Asian (SEA) countries including India. The pathogenesis of this disease is not clearly understood and is probably
attributed to genomic variations in viral strains as well as the host genetic makeup. The present study is to
determine the role of polymorphism of TNF-alpha promoter regions at positions -238G/A, -308G/A, -857C/T and
-863C/A in the severity of Japanese encephalitis patients.
Methods: Total of 142 patients including 66 encephalitis case (IgM/RT-PCR positive), 16 fever cases (IgM positive)
without encephalitis and 60 apparently healthy individuals (IgG positive) were included in the study. Polymerase
chain reaction restriction fragment length polymorphism (PCR-RFLP) using site specific restriction enzymes were
implemented for polymorphism study of TNF alpha promoter.
Results: Following the analysis of the digestion patterns of four polymorphic sites of the TNF- alpha promoter
region, a significant association was observed between the allele -308A and -863C with the patients of Japanese
encephalitis.
Conclusions: TNF- alpha 308 G/A has been shown to be associated with elevated TNF- alpha transcriptional
activity. On the other hand, polymorphism at position -863C/A in the promoter region has been reported to be
associated with reduced TNF- alpha promoter activity and lower plasma TNF levels. As per the literature search, this
is the first study to identify the role of TNF- alpha promoter in JE infection. Our results show that subjects with -
308A and -863C alleles are more vulnerable to the severe form of JE infection.
Background
Japanese encephalitis (JE) is an important flaviviral dis-
ease of public health concern in Eastern and South-East
Asian (SEA) countries. Approximately 50,000 cases are
being reported annually to WHO with a case fatality of
10,000 cases [1]. On account of globalization and cli-
matic change, there is a gradual spread of the virus into
naïve geographical areas including Australia and UK,
however, fortunately there is no report of local spread of
JE in UK [2,3]. In the past, the neurotropic nature of
Japanese encephalitis virus (JEV) often posed epidemic
threats of acute encephalitic syndrome (AES) in SEA
countries including the Indian subcontinent [4,5].
Commonly the spectrum of JEV infection ranges from
an asymptomatic infection to meningoencephalomyelitis
with cortical damage and cord lesions. An overt case of
JE carries a poor prognosis with a mortality of 10-30%;
one third of recovered cases land into neurological
sequelae whereas complete recovery is expected in the
remaining one third of patients [6].
Tumor necrosis factor is a multifunctional pro-inflam-
matory cytokine with a role in modulation of acute
inflammation and host innate immunity. Its association
towards disease progression has well been observed in
several acute and chronic infections and autoimmune
diseases. The reactivation of latent tuberculosis follow-
ing treatment with anti-TNF antibody (Infliximab) has
been reported [11], indicating TNF as a key cytokine
towards the development of resistance to the tubercle
bacilli and other intracellular pathogens. Even an excess
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cerebral malaria, erythema nodosum leprosum and
leishmaniasis [12-17].
The variations in the capacity to produce cytokines in
different individuals have been attributed to the exis-
tence of polymorphisms within the regulatory regions or
signal sequences of the cytokine genes. The present
study aimed to associate the role of TNF-a promoter
regions at positions -238, -308, -857 and -863 with dis-
ease progression and outcome in patients with Japanese
encephalitis. The single nucleotide polymorphisms
(SNPs) have been targeted because of their putative role
on the promoter activity which might influence the
TNF-a production and immunologic homeostasis.
Methods
All the subjects (n: 142) included in the study were
enrolled during the post monsoon period (August-
December 2007-2009) i.e. JEV transmission season
with informed consent. Of the total, 66 were JE
patients [IgM (n: 56)/RT-PCR (n: 10) positive] with
encephalitic features collected from inpatients depart-
ments of PGIMER, Chandigarh, 16 were JE IgM posi-
tive cases who presented with acute febrile illness and
t h er e s t( n :6 0 )w e r ea p p a r e n t l yh e a l t h ys u b j e c t sp r e -
viously exposed to JEV infection (confirmed by detec-
tion of JEV specific IgG antibody) collected from the
rural areas endemic to Japanese encephalitis belonging
to the neighboring rice growing states of Chandigarh.
A clinical-case definition of JE was followed as per
National Vector Borne Disease Control Programme,
Govt. of India. Febrile illness of variable severity asso-
ciated with neurological symptoms ranging from head-
ache to meningitis or encephalitis were labeled as
A c u t eE n c e p h a l i t i cS y n d r o m e( A E S ) .S y m p t o m sc a n
include headache, fever, meningeal sign, disorientation,
coma, tremor, generalized paralysis, hypertonia and
loss of coordination. Patients with suspected AES
showing JE specific IgM antibody in the cerebro-spinal
fluid (CSF) only/in paired samples of CSF and blood
or JEV RNA in CSF [9,18] are labeled as confirmed JE
cases whereas those with only JE IgM positivity in
serum are considered as probable JE cases [19]. The
possibility of cross-reactive antibodies to dengue virus
was taken into account and all the samples (fever,
encephalitis) were also screened for dengue specific
IgM antibodies (Dengue specific IgM Ab ELISA; NIV,
Pune, India) and were found to be nonreactive. From
each subject, approximately 3 ml of blood was col-
lected aseptically by trained health personnel for geno-
mic DNA extraction (1 ml anti-coagulated blood) and
viral serology (2 ml blood in sterile plain vial). The
details of serology and viral genome detection proce-
dures were described previously [9].
Genomic DNA was extracted as per the manufac-
turer’s protocol using QIAGEN DNA extraction kit. For
the detection of SNPs at TNF-a promoter region, gene
specific PCR was performed followed by restriction frag-
ment length polymorphism (PCR-RFLP). The positions
-863C/A, -857C/T, -308G/A, and -238G/A were ampli-
fied using the published primer sequences and amplifi-
cation profiles [20]. These PCR products were further
subjected to restriction digestion with respective restric-
tion enzymes as shown in Table 1 and the digested pro-
ducts were observed in ethidium bromide stained 3%
agarose gel. The allelic type was determined according
to the presence or absence of the digested product of
the desired length. Adequate precautionary measures
were taken for cross contamination during PCR amplifi-
cation; RFLP and 50% of the samples were repeated to
maintain the quality of the data.
Statistical analysis
The data was evaluated by chi-square (c
2) analysis using
standard statistical software with a P value of < 0.05
being statistically significant. Genotypic frequencies were
examined by Hardy-Weinberg equilibrium test. EPI ver-
sion 6.2 was implemented for estimation of the c
2 value,
odds ratios and 95% confidence intervals for genotypic
and allelic frequencies.
Results
Demographic characteristics of the subjects
The male:female ratio in the encephalitis, fever and con-
trol groups were 55/11, 10/6 and 19/41 respectively. It
was interesting to note that children below 16 years age
group were more affected and males outnumbered the
females in the group of patients with encephalitic fea-
tures (Table 2).
Table 1 Restriction enzymes and digestion patterns for
genotyping of TNF promoters
Promoter
position
Restioction
enzymes
Digestion
patterns
Genotypes
-238 G/A MspI 132,20 GG
152,132, 20 GA
152 GG
-308 G/A StyI 123,20 GG
143,123,20 GA
143 AA
-857 C/T HincII 106 25 CC
131,106 25 CT
131 TT
-863 C/A StyI 108, 25 CC
133,108, 25 CA
133 AA
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The genotypic and allelic frequencies of -863C/A,
-857C/T, -308G/A, and -238G/A were calculated (Table
3). Allele and genotypic frequencies were in Hardy-
Weinberg equilibrium. The frequency distribution of the
homozygous GG and heterozygous GA at -308 in ence-
phalitis group was statistically significant when com-
pared with fever (GG: Χ
2 = 15.96, p = 0.001**, OR =
11.56, 95% CI = 2.61-58.51; GA: Χ
2 = 15.96, p = 0.001**,
OR = 0.09, 95% CI = 0.02-0.38) and control group (GG:
Χ
2 = 42.28, p = 0.001**, OR = 15.11, 95% CI = 5.73-
41.35; GA: Χ
2 = 42.28, p = 0.001**, OR = 00.07, 95% CI
= 0.02-0.17). Again the distribution of the homozygous
CC and heterozygous CA genotypes at -863 in encepha-
litis groups were statistically significant as compared
with control group (CC: Χ
2 = 23.51, p = 0.001**, OR =
0.12, 95% CI = 0.04-0.33; CA: Χ
2 = 11.69, p = 0.001**,
OR = 9.74, 95% CI = 1.96-65.38) (Table 4). Out of the
66 encephalitis patients, 9 had fatal outcome, of which 7
had the typical allelic distribution of -308A and -863 C
genotypes.
Discussion
The human and murine model studies revealed that the
outcome in infectious diseas e si si n f l u e n c e db yT N F - a.
In meningococcal meningitis patients, low TNF-a pro-
duction is associated with tenfold increase in mortality
[21] whereas the severity of the disease is directly pro-
portional to the TNF-a levels in CSF and blood of JE
patients [10].
The patho-physiology of the CNS entry by neurotropic
viruses is still an enigma. The role of inflammatory cyto-
kines has been amply emphasized towards disrupting the
integrity of the blood brain barrier in West Nile Virus
(WNV) infections. TLR-3 mediated expression of TNF-a
l e a d st ol o s so fi n t e g r i t yo fthe endothelial cells in the
brain, possibly by mediating the passage of viral particles
and virus loaded immune cells into the CNS [22,23].
Following JE infection, approximately 1 in 300-1,000
persons would turn out with acute encephalitis and
majority abort the infection sub clinically. The present
study was aimed at the host factors governing pathogen-
esis of JE. There is no correlation between the disease
severity and the circulating JE genotypes. However, a
possible correlation is observed between the severity of
JE and the level of JEV specific IgM antibody in the
serum and CSF [10].
The TNF-a gene is located within the class III region
of the major histocompatibility complex (MHC) between
HLA-B and DR, (Figure 1) and its expression in the host
is controlled in a regulated manner at the transcriptional
as well as post transcriptional level. Polymorphism of
TNF-a promoter region has been shown to play a role
in the development of autoimmune diseases and several
infections like malaria, leishmaniasis, hepatitis B virus,
hepatitis C virus, human papiloma virus etc.
[13,15,17,24].
The -308A allele in the TNF-a promoter (also known
as TNF2) is a G/A transition and is the most studied
SNP in this gene. In case of HBV infection, the presence
of -308A and -863C was associated with viral clearance
[15], whereas SNP -238G has been shown to be asso-
ciated with protection against chronic hepatitis in the
Chinese and German population [14,16]. In hepatitis C
virus infection, the haplotype -863C/-308G was asso-
ciated with viral persistence in African Americans [12].
Similarly the existence of -308A SNP in pediatric popu-
lation positively correlated with the severity of dengue
viral infection in children.
Table 2 Subject details
Encephalitis (n = 66) Fever (n = 16) Control (60) Χ
2 P Value
Age (Year mean ± SD) 16 ± 12.543 30.76 ± 14.942 21.72 ± 10.187 23.902 .001**
Sex(Male/Female) 55/11 10/6 19/41 29.148 .001**
Male/Female in % 83.3/16.7 62.5/37.5 31.7/68.3
Table 3 Genotypic and allelic frequencies of TNF-a
polymorphism
Control Encephalitis Fever
-238 GA 4(6.7%) 6(9.1%) 2(12.5%)
GG 56(93.3%) 60(90.9%) 14(87.5%)
G 96.67 95.45 93.75
A 3.33 4.5 6.25
-308 GA 9(15.0%) 48(72.7%) 3(18.75%)
GG 51(85.0%) 18(27.3%) 13(81.25%)
G 92.5 36.37 90.62
A 7.5 63.63 9.38
-857 CC 41(68.3%) 50(75.8%) 12(75%)
CT 19(31.7%) 10(15.2%) 4(25%)
TT 0 6(9.1%) 0
C 84.16 83.33 87.5
T 15.84 16.67 12.5
-863 AA 16(26.7%) 5(7.6%) 1(6.25%)
CA 14(23.3%) 2(3.0%) 0
CC 30(50.0%) 59(89.4%) 15(93.75%)
A 38.33 9.09 96.87
C 61.67 90.91 3.13
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a promoter region at positions -863C/A, -857C/T,
-308G/A and -238G/A with reference to the transcrip-
tion start site have been analyzed based upon the TNF
secretion capacity. TNF-a -308G/A has been shown to
be associated with elevated TNF-a transcriptional
activity. On the other hand, polymorphism at position
-863C/A in the promoter region has been reported to
be associated with reduced TNF-a promoter activity
and lower plasma TNF levels. As per the literature
search, this is the first study to identify the role of
TNF-a promoter in JE infection. Our results show that
subjects with -308A and -863C alleles are more vulner-
able to the severe form of JE infection. Logistic regres-
sion could not be performed in this study due to
limited numbers of events which happens to be one of
the limitations and warrants caution with regards to
the conclusion.
Table 4 Statistical comparison of Genotypic and allelic frequencies of TNF-a polymorphism between different groups
Control Vs Encephalitis Control Vs Fever Fever Vs Encephalitis
Loci Genotype Χ
2 Value P-Value OR 95% CI Χ
2 Value P-Value OR 95% CI Χ
2 Value P-Value OR 95% CI
-238 GA 0.25 0.43 0.71 0.16-3.06 0.59 0.44 0.5 0.07-4.42 0.17 0.48 1.43 0.18-9.28
GG 0.25 0.43 1.4 0.33-6.29 0.59 0.44 2 0.23-14.90 0.17 0.48 0.7 0.11-5.64
-308 GA 42.28 0.001** 00.07 0.02-0.17 0.13 0.48 0.76 0.15-4.17 15.96 0.001** 0.09 0.02-0.38
GG 42.28 0.001** 15.11 5.73-41.35 0.13 0.48 1.31 0.24-6.47 15.96 0.001** 11.56 2.61-58.51
-857 CC 0.86 0.35 0.69 0.29-1.62 0.27 0.42 0.72 0.17-2.87 0.001 0.58 0.96 0.24-4.13
CT 4.84 0.02 2.60 1.01-6.76 0.27 0.42 1.39 0.35-5.39 0.88 0.27 1.87 0.41-8.13
TT 6.93 0.01 3.03 0.07 5.45 0.65-119.49 26.7 0.001
-863 AA 8.25 0.04 4.44 1.38-15.09 4.56 0.03 0.03 0.66 0.81
CA 11.69 0.001** 9.74 1.96-65.38 10.01 0.001** 0.07 0.00-0.54 0.50 0.64
CC 23.51 0.001** 0.12 0.04-0.33 0.59 0.44 0.5 0.07-4.42 0.28 0.51 1.78 0.19-41.45
Figure 1 Map of TNF-a promoter and TNF-&#945 gene on chromosome 6. Animal studies have pointed towards the association of
particular single and/or multiple nucleotide changes in the viral genome with altered virulence but the degree of severity and disease outcome
in JE do not correlate with virus genotypes [7-9]. Thus, the concept of the host genetic makeup towards disease modulation has been
postulated. Elevated levels of tumor necrosis factor alpha (TNF-a), a central mediator of immune response, in both serum and CSF samples in
patients with JE have been associated with poor prognosis [10].
Pujhari et al. BMC Infectious Diseases 2012, 12:23
http://www.biomedcentral.com/1471-2334/12/23
Page 4 of 6A combined effect of prolonged exposure to high level
of pro-inflammatory cytokines (TNF-a) combined with
reduced release of anti-inflammatory cytokines IL-10
and IL-4 in encephalitis conditions may cause immuno-
logic imbalance landed with poor prognosis [25]. Host
genetic display of cytokine genes and their regulatory
sequence alters the expression patterns of the different
cytokines. In summary, the present study supports the
potential role of genetic variation in the TNF-a promo-
ter region in susceptibility to JEV infection.
Conclusion
Subjects with -308A and -863C alleles were more vul-
nerable to the severe form of JE infection and of the
total 9 deaths, 7 had -308A and -863C allelic distribu-
tion. At the verge of entering into the era of persona-
lized medicine, understanding the association of
mutations with infectious disease is very important. This
information will help the physician to become aware of
a prior possible outcome of the patient and thus to fol-
low an appropriate management protocol for the
patients.
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